Retevmo (selpercatinib)
pCPA File Number:
21931
Negotiation Status:
Concluded with an LOI
Indication(s):
Differentiated thyroid carcinoma (DTC), Rearranged during transfection (RET) fusion-positive, in adult patients with advanced or metastatic disease (not amenable to surgery or radioactive iodine therapy) monotherapy treatment following prior treatment with sorafenib and/or lenvatinib
Sponsor/Manufacturer:
Eli Lilly Canada Inc.
CDA-AMC Project Number:
PC0274
pCPA Engagement Letter Issued:
Negotiation Process Concluded: